Biologics and biosimilars
In-depth global knowledge of this rapidly maturing field which straddles numerous therapy areas. For five years, I worked closely with IQVIA’s Biosimilars Center of Excellence to produce regular insight pieces on scientific, clinical, regulatory, financial and political developments in the field and have advised several companies on their biosimilars communication programmes.
I have co-authored two published papers on biosimilars. For the 2017 article A Decade of Biosimilars: Have Expectations Been Met? click here and for the 2019 article Use of Big Data to Aid Patient Recruitment for Clinical Trials Involving Biosimilars and Rare Diseases click here
Experienced in primary and secondary prevention of atherosclerotic conditions, and the management of heart failure
Extensive work on oral hypoglycaemic options, insulins, blood glucose monitoring advances, management of complications
Closely involved with the UK launch of beta interferon over 20 years ago and the burgeoning of disease-modifying options since then
Significant experience in both asthma and COPD
Experience is particularly notable in schizophrenia but also depression in its various forms
Steadily accumulating experience in rare genetic, autoimmune and autoinflammatory conditions
For areas where my experience is less established, I am generally able to get up to speed quickly with the status quo of clinical practice, unmet needs and key issues.